Taysha Gene Therapies, Inc.
TSHA
$5.95
-$0.04-0.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 171.27% | -- | 78.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 171.27% | -- | 78.60% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 171.27% | -- | 78.60% |
| SG&A Expenses | 41.27% | 18.62% | 33.25% | 4.77% | 17.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.76% | 83.31% | 53.89% | 48.91% | 28.24% |
| Operating Income | -76.99% | -103.01% | -41.98% | -61.56% | -25.61% |
| Income Before Tax | -73.50% | -96.99% | -48.26% | -28.24% | -28.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.50% | -96.99% | -48.26% | -28.24% | -28.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.50% | -96.99% | -48.26% | -28.24% | -28.45% |
| EBIT | -76.99% | -103.01% | -41.98% | -61.56% | -25.61% |
| EBITDA | -77.74% | -104.33% | -42.66% | -62.47% | -26.21% |
| EPS Basic | -40.13% | -44.81% | -11.29% | 2.83% | -0.33% |
| Normalized Basic EPS | -43.34% | -50.43% | -14.50% | -19.88% | -1.14% |
| EPS Diluted | -40.13% | -44.81% | -11.29% | 2.83% | -0.33% |
| Normalized Diluted EPS | -43.34% | -50.43% | -14.50% | -19.88% | -1.14% |
| Average Basic Shares Outstanding | 23.84% | 36.14% | 33.14% | 31.92% | 27.99% |
| Average Diluted Shares Outstanding | 23.84% | 36.14% | 33.14% | 31.92% | 27.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |